User:Ingyjabri/sandbox

From Wikipedia, the free encyclopedia

Breast Cancer Cell Lines[edit]

Breast cancer cell lines are permanently established, immortalized cultures of cells that differentiate and proliferate indefinitely through random mutation or modification when subjected to a suitable medium and space.[1] They are extensively cultivated and used to study breast cancer biology in hopes of contributing to the ongoing discovery of breast cancer therapies developed by analyzing gene function.[2] These cell lines are activated from a range of tumor types, from primary to metastatic.[2] Depending on the tumor source that the cells are isolated from, the different types of cell lines will have varying antigenic expression profiles.[2] Common types of breast cancer cell lines include MCF-7, SK-BR-3, MDA-MB-231, and T-47D. They are easy to handle and have the potential to grow in infinite quantities.[3]

Cell Culture Techniques[edit]

Among the many cell culture techniques for the culturing and engineering of stable cell lines, two are widely used, the spillage technique (originally described in 1958) and the enzyme dispersal technique.[3] Scientists choose a particular technique depending on its relevance to their experiment, their accessibility to certain materials, and the precision of their method.[3] In the spillage technique the tumor is cut open, the cancer cells are allowed to spill out and are collected.[4] In the enzymatic dispersal technique, the breast cancer tissue from the tumor is collected, cut into small fragments, washed and treated with collagenase lll enzyme allowing the enzyme to mechanically digest the tumor cell fragments.[4] To separate organoid, epithelial and stromal breast cells depending on their density, the fragmented tissue are centrifuged by a process called differential centrifugation.[3] Other techniques rely on sedimentation rates for cells of differing sizes that are also separated using differential centrifugation.[3] After the cell lines are constructed and allowed to grow in selective media, they can be used in vivo or in vitro depending on the purpose of the experiment.

Common Types[edit]

MCF-7[edit]

In 1970, a 69-year-old Caucasian woman isolated the MCF-7 breast cancer cell line.[5] Later in 1973, Dr. Herbert Soule along with his coworkers then established the cell line at the Michigan Cancer Foundation in Detroit.[5] The MCF-7 cell line is usually found in invasive breast ductal carcinoma and is the most commonly used cell line in experiments today.[6] MCF-7 was derived from a pleural effusion extracted from a patient with metastatic breast cancer.[6] Antiestrogen is a substance that inhibits the production and use of estrogen in cells, therefore, the ability of pure antiestrogens to control the growth of tamoxifen-stimulated MCF-7 tumors presented strong evidence that progressed to clinical trials.[6] The cells were found to contain estrogen and progesterone receptors and cause tumorigenicity in mice.[7]

MCF-7 Cells

SK-BR-3[edit]

Discovered in the late 1970s, the breast cancer cell line SK-BR-3 was derived from a pleural effusion in an invasive ductal carcinoma found in a patient’s breast.[8] Most breast cancer cells tend to over express the human epidermal growth factor receptor 2 HER2.[8] Most studies use SK-BR-3 cell line to investigate the issue of overcoming the resistance of Herceptin in those breast cancer cells.[8] Additionally, SK-BR-3 breast cancer cells have a high potential of invasion and migration as shown in the study including up regulation of the membrane protein GPR30 in SK-BR-3 breast cancer cells by Heregulin-B1 derived from tumor cells.[9]

MDA-MB[edit]

A range of MDA-MB cell lines was discovered in 1978.[6] All were found to have metastatic origin and located in the primary tumor invasive ductal carcinoma.[6] The nineteen different types exhibited varying growth rates and patterns.[6] MDA-MB 134, 453, 468, and 469 were shown to be single cells or groups of loosely attached cells which are easily shaken off, MDA-MB 175, 309, 331, 390, and 416 are very tightly stuck to each other, and MDA-MB 415, 431, and 435 are flat and have clear cut figures.[6] MD-MB 231 and 436 cells grow randomly and are spindle-shaped, and MDA-MB 175 and 330 have been shown to stick to one another and to other larger and smaller types to form a single colony.[6] The cells within the colony have potential to grow and differentiate into different specialized cells with varying functions.[6] Factors like Pinolenic acid and methotrexate proline prodrug are known to inhibit the human breast cancer MDA-MB-231 cells.[10][11]

T-47D[edit]

T-47D cells form tight cohesive structures between cells and express the estrogen receptor naturally.[12] Similar to MCF-7, T-47D have high tumorigenicity potential and can be inhibited by anti-estrogen therapy.[13] A study examined a specific and receptive estrogen-responsive gene expression assay, that can be used for the screening of potential anti-estrogenic chemicals using T-47D cells.[12] There are multiple advantages and disadvantages in working with cell lines and with primary cell cultures in comparison to distant metastatic cultures.

Advantages[edit]

Advantages of using cell lines in experimentation and therapy development include their ability to grow infinitely, their ease of use, their moderately high levels of homogeneity, and their ability to be replaced by frozen cultures when contaminated.[3] Furthermore, cell-to-cell interactions are lost in tissues cultured in vitro, therefore, experiments have shown that isolated primary cells have been demonstrating the maintenance of those interactions in vitro.[3]

Disadvantages[edit]

The main disadvantage of using cell lines is that they have a continuous growing culture and are prone to genetic and phenotypic drift as seen with cell line MCF-7.[3] Despite the fact that cells of a particular type exhibit the same morphology, sometimes cells in an established cell line can be found to have varying hormone receptor content and cellular growth rates.[3] This gives rise to challenges when scientists are trying to grow and use cells of identical biological content. The most important limitation of a primary culture is its slow cellular population doubling time.[3] Because tumors are heterogeneous, the desired isolated epithelial cells might be contaminated by the normal epithelial cells.[3] Therefore, choosing the appropriate cell culture for a specific cell line and experiment is vital to maximize their usage and to take advantage of their distinct properties.

References[edit]

  1. ^ Dictionary, C. "Cell Line". Biology Online. Retrieved 17 March 2013.
  2. ^ a b c Mosoyan, Goar; Nagi, Chandandeep; Marukian, Svetlana; Teixeira, Avelino; Simonian, Anait; Resnick-Silverman, Lois; Difeo, Analisa; Johnston, Dean; Reynolds, Sandra R.; Roses, Daniel F.; Mosoian, Arevik (January 2013). "Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential". PLOS ONE. 8 (1): e55145. doi:10.1371/journal.pone.0055145. PMC 3555897. PMID 23372829.{{cite journal}}: CS1 maint: date and year (link)
  3. ^ a b c d e f g h i j k Burdall, Sarah E.; Hanby, Andrew M.; Lansdown, Mark RJ; Speirs, Valerie (February 2003). "Breast cancer cell lines: friend or foe?". Breast Cancer Research. 5 (2): 89–95. doi:10.1186/bcr577. PMC 154155. PMID 12631387. S2CID 6441014.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: unflagged free DOI (link)
  4. ^ a b LASFARGUES EY; OZZELLO L (December 1958). "Cultivation of human breast carcinomas". Journal of the National Cancer Institute. 21 (6): 1131–1147. PMID 13611537.{{cite journal}}: CS1 maint: date and year (link)
  5. ^ a b Soule, H. D.; Vazquez, J.; Long, A.; Albert, S.; Brennan, M. (July 1973). "A human cell line from a pleural effusion derived from a breast carcinoma". Journal of National Cancer Institute. 51 (5): 1409–1416. doi:10.1093/jnci/51.5.1409. PMID 4357757.{{cite journal}}: CS1 maint: date and year (link)
  6. ^ a b c d e f g h i Cailleau, Relda; Olivé, Matilde; Cruciger, Quita V. J. (November 1978). "Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization". In Vitro. 14 (11): 911–915. doi:10.1007/BF02616120. PMID 730202. S2CID 33567549.{{cite journal}}: CS1 maint: date and year (link)
  7. ^ Levenson, A. S.; Jordan, V. C. (April 1997). "MCF-7: the first hormone-responsive breast cancer cell line". Cancer Research. 57 (15): 3071–3078. PMID 9242427.{{cite journal}}: CS1 maint: date and year (link)
  8. ^ a b c Tseng, Ping-Hui; Wang, Yu-Chieh; Weng, Shu-Chuan; Weng, Jing-Ru; Chen, Chang-Shi; Brueggemeier, Robert W.; Shapiro, Charles L.; Chen, Ching-Yu; Dunn, Sandra E.; Pollak, Michael; Chen, Ching-Shih (August 2006). "Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor" (PDF). Molecular Pharmacology. 70 (5): 1534–1541. doi:10.1124/mol.106.023911. PMID 16887935. S2CID 222111.{{cite journal}}: CS1 maint: date and year (link)
  9. ^ Ruan, Shu-Qin; Wang, Zhan-Huai; Wang, Shan-Wei; Fu, Zhi-Xuan; Xu, Kan-Lun; Li, Dong-Bo; Zhang, Su-Zhan (April 2012). "Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3–MAPK/ERK pathway". Biochemical and Biophysical Research Communucations. 420 (2): 385–390. doi:10.1016/j.bbrc.2012.03.004. PMID 22425775.{{cite journal}}: CS1 maint: date and year (link)
  10. ^ Chen, Szu-Jung; Hsu, Chih-Ping; Li, Chi-Wei; Lu, Jui-Hua; Chuang, Lu-Te (June 2011). "Pinolenic acid inhibits human breast cancer MDA-MB-231 cell metastasis in vitro". Food Chemistry. 126 (4): 1708–1715. doi:10.1016/j.foodchem.2010.12.064. PMID 25213948.{{cite journal}}: CS1 maint: date and year (link)
  11. ^ Wu, Zhiqian; Shah, Anandkumar; Patel, Namrata; Yuan, Xudong (September 2010). "Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells". Bioorganic & Medicinal Chemistry Letters. 20 (17): 5108–5112. doi:10.1016/j.bmcl.2010.07.024. PMID 20674353.{{cite journal}}: CS1 maint: date and year (link)
  12. ^ a b Holliday, Deborah L.; Speirs, Valerie (August 2011). "Choosing the right cell line for breast cancer research". Breast Cancer Research. 13 (215): 215. doi:10.1186/bcr2889. PMC 3236329. PMID 21884641.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: unflagged free DOI (link)
  13. ^ Wilson, V. S.; Bobseine, K.; Gray Jr, L. E. (May 2004). ". Development and characterization of a cell line that stably expresses an estrogen responsive luciferase reporter for the detection of estrogen receptor agonist and antagonist". Toxicological Sciences. 81 (1): 69–77. doi:10.1093/toxsci/kfh180. PMID 15166400.{{cite journal}}: CS1 maint: date and year (link)